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ARTICLE
A New Genetic Disorder in Mitochondrial Fatty Acid b-Oxidation:
ACAD9 Deficiency
M. He, S. L. Rutledge, D. R. Kelly, C. A. Palmer, G. Murdoch, N. Majumder, R. D. Nicholls, Z. Pei,
P. A. Watkins, and J. Vockley
The acyl-CoA dehydrogenases are a family of multimeric flavoenzymes that catalyze the a,b-dehydrogenation of acyl-
CoA esters in fatty acid b-oxidation and amino acid catabolism. Genetic defects have been identified in most of the acyl-
CoA dehydrogenases in humans. Acyl-CoA dehydrogenase 9 (ACAD9) is a recently identified acyl-CoA dehydrogenase
that demonstrates maximum activity with unsaturated long-chain acyl-CoAs. We now report three cases of ACAD9
deficiency. Patient 1 was a 14-year-old, previously healthy boy who died of a Reye-like episode and cerebellar stroke
triggered by a mild viral illness and ingestion of aspirin. Patient 2 was a 10-year-old girl who first presented at age 4 mo
with recurrent episodes of acute liver dysfunction and hypoglycemia, with otherwise minor illnesses. Patient 3 was a
4.5-year-old girl who died of cardiomyopathy and whose sibling also died of cardiomyopathy at age 21 mo. Mild chronic
neurologic dysfunction was reported in all three patients. Defects in ACAD9 mRNA were identified in the first two
patients, and all patients manifested marked defects in ACAD9 protein. Despite a significant overlap of substrate specificity,
it appears that ACAD9 and very-long-chain acyl-CoA dehydrogenase are unable to compensate for each other in patients
with either deficiency. Studies of the tissue distribution and gene regulation of ACAD9 and very-long-chain acyl-CoA
dehydrogenase identify the presence of two independently regulated functional pathways for long-chain fat metabolism,
indicating that these two enzymes are likely to be involved in different physiological functions.
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The acyl-CoA dehydrogenases (ACADs) are a group of mi-
tochondrial flavoenzymes that catalyze the a,b-dehydro-
genation of acyl-CoA esters, using the electron transfer
flavoprotein (ETF) as their physiologic electron acceptor.
There are at least nine known members of the ACAD gene
family active in branched-chain amino acid catabolism or
fatty acid oxidation. All of the ACADs are nuclear-encoded
proteins that must first be translated in the cytoplasm,
then imported into mitochondria and processed into a
mature form.
Deficiencies of the ACADs are among the most common
inborn errors of metabolism. Seven different ACAD ge-
netic defects have been described in the past.1 ACAD-de-
ficient patients typically accumulate intermediate metab-
olites with profiles that reflect the substrate specificity of
the deficient enzyme. However, of the three long-chain–
specific ACADs, inherited defects have been identified
only in very-long-chain ACAD (VLCAD) (ACADVL [MIM
609575]). Patients present with recurrent episodes of hy-
poglycemia with or without rhabdomyolysis, sudden un-
explained death, and cardiomyopathy.1 Recently, tandem
mass spectrometry has been used to detect characteristic
metabolites in blood spots collected from newborns, al-
lowing diagnosis of VLCAD deficiency before symptoms
develop.2 Long-chain ACAD (LCAD) was characterized
about a decade before VLCAD was discovered3; however,
its physiologic function remains a mystery. Acyl-CoA
dehydrogenase 9 (ACAD9) has only recently been rec-
ognized.4,5 Substrate-utilization studies have shown that
ACAD9 is active against both saturated and unsaturated
long-chain acyl-CoA substrates, with optimum activity to-
ward the latter.4 In this article, we report three cases of
ACAD9 deficiency presenting with episodic liver dysfunc-
tion during otherwise mild illnesses or cardiomyopathy,
along with chronic neurologic dysfunction. In spite of the
high degree of homology between ACAD9 and VLCAD, it
is clear that their physiological functions do not comple-
ment each other when either is deficient.6 Rather, our
studies of the enzymatic function, tissue distribution, and
gene expression of these two enzymes identify the pres-
ence of two independently regulated functional pathways
for long-chain fat metabolism and expand the potential
role for fatty acid oxidation in intermediary metabolism.
Methods
Overexpression and Purification of Long-Chain ACADs
Full-length cDNAs corresponding to the mature protein sequence
of ACAD9, VLCAD, and LCAD were cloned individually into the
Escherichia coli expression vector pET-21a() (Novagen) and were
overexpressed, and the proteins were purified as described
elsewhere.4,7 The purity of each enzyme was estimated, by SDS-
PAGE, to be 195%.
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Quantitative Real-Time RT-PCR
Reverse transcription was performed using a panel of total RNA
pooled from 20 human tissues or total RNA pooled from human
hippocampus (purchased from BD Biosciences Clontech), with 1
mg of RNA and Powerscript reverse transcriptase (BD Biosciences
Clontech), in accordance with the manufacturer’s instructions.
cDNA corresponding to 20 ng of total RNA was used for real-time
RT-PCR on an ABI 7900HT Sequence Detection System (PE Ap-
plied Biosystems), with the use of heat-activated TaqDNA poly-
merase (BD Biosciences Clontech). Specific probes and primers
(sequences available on request) for VLCAD, ACAD9, LCAD, me-
dium-chain ACAD (MCAD), and short-chain ACAD (SCAD) were
designed to target near the coding sequence for the catalytic do-
main of each enzyme. Probes for the housekeeping gene glucu-
ronidase, beta (GUSB) and the 18S ribosomal RNA (rRNA) gene
were used as controls. All the probes and primers were synthesized
by PE Applied Biosystems (Assay on Demand). PCR assays were
performed in 96-well optical plates, in accordance with the man-
ufacturer’s recommendations. The amplification efficiency of
primer and probe sets was tested using different dilutions of total
RNA, and all were similar (close to 1). For quantitative analysis
of the data, CT (threshold-cycle number) values were normalized
to those of GUSB or 18S rRNA, with use of the DDCT method.
8
cDNA Amplification and Sequencing
Total RNA was extracted from patient fibroblasts or frozen post-
mortem liver with the use of TRIzol reagent (Invitrogen) in ac-
cordance with the manufacturer’s instructions. Reverse transcrip-
tion was performed using 1 mg of total RNA and Powerscript
reverse transcriptase, with the use of random hexamers as prim-
ers. The ACAD9 coding region was then amplified with the Yiel-
dace PCR kit (Stratagene), with primers as follows: 5′-AGACGTGT-
GTGTGTCCCTGCGGCGCTA-3′ and 5′-GAGTAACAGTCATCCA-
GCAACGGGCCATGGGTA-3′. Various primers at intron/exon
junctions of ACAD9 were also used, and their sequences are
available on request. The PCR products were purified using the
PCR Cleanup kit (Qiagen) and were sequenced directly by the
Genomics and Proteomics Core Facility at the University of
Pittsburgh.
Immunoblotting and Immunocompetition Assay
Fifty micrograms of total protein from human fibroblast or liver
extracts and 150 mg of total protein from muscle lysates were
separated on a 12% SDS polyacrylamide gel, were transferred to
nitrocellulose, and were immunostained with the indicated an-
tibodies, by use of our previously published methods.4 Immu-
nocompetition assays were performed similar to routine immu-
nobloting, except that purified ACAD9 protein was added to the
antibody incubation solution. The ratio between purified ACAD9
protein and affinity-purified ACAD9 antibody was 1:1 (mole:
mole).
ETF Fluorescence-Reduction Assay for ACAD Activity
ACAD activity in cultured skin fibroblasts and frozen liver ob-
tained 6–10 h postmortem from patient 1 and an age-matched
control who died of trauma (Brain and Tissue Bank for Devel-
opmental Disorders, Baltimore) was assayed using the sensitive
and specific anaerobic ETF fluorescence-reduction assay with the
indicated substrates at 5 mM final concentration, as described else-
where.9 Mitochondrial matrix and membrane fractions were pre-
pared and assayed in triplicate, with use of palmitoyl (C16:0)-
CoA as substrate, as described elsewhere.10 Five normal liver
samples were used as controls. Saturated and monounsaturated
straight-chain acyl-CoA substrates—hexanoyl (C6:0)–CoA, oc-
tanoyl (C8:0)–CoA, decanoyl (C10:0)–CoA, dodecanoyl (C12:0)–
CoA, tetradecanoyl (C14:0)–CoA, C16:0–CoA, palmitoleoyl
(C16:1)–CoA, stearoyl (C18:0)–CoA, octadecenoyl (C18:1)–CoA,
octadecynoyl (C18:2)–CoA, and arachidoyl (C20:0)–CoA—were
purchased from Sigma. Arachidonoyl (C20:4)–CoA and docosah-
exaenoyl (C22:6)–CoA were purchased from Avanti Polar Lipids.
Branched-chain and some polyunsaturated-chain acyl-CoA sub-
strates included the CoA ester of 3a, 7a, l2a-trihydroxy-5b-cho-
lestan-26-oic acid (THC-CoA); S, 2-methyl-hexadecanoyl-CoA (S,
2-methyl C16-CoA); S, 2-methyl-pentadecanoyl-CoA (S, 2-methyl
C15-CoA); S, 4, 8, 12 trimethyl-tridecanoyl-CoA (S, 4, 8, 12, tri-
methyl C13-CoA); eicosapentaenoyl (C20:5)-CoA (kindly pro-
vided by Dr. Paul P. Veldhoven [Leuven University, Belgium]),
and S, 2,6-dimethylheptanoyl-CoA (S, dimethyl C7-CoA) (kindly
provided by Dr. R. J. A. Wanders [University of Amsterdam]). Cy-
tokine stimulation of cultured human fibroblasts was performed
as described elsewhere.11 ACAD activity was assayed in cultures
before and after stimulation.
Immunoinactivation of Purified ACAD9
A rabbit polyclonal antiserum was raised to ACAD9 and was pu-
rified through a Staphylococcus aureus protein A column (Pierce),
in accordance with the manufacturer’s instructions. For immu-
noinactivation assays, 1 mg of purified antibody was added per
10 mg of liver lysate protein. The mixture was incubated at 4C
overnight, with gentle mixing. The next morning, protein A–
bound resin was added to the mixture and was incubated at 4C
for an additional hour, and bound antibody complex was pre-
cipitated by centrifugation. The supernatant was assayed for
ACAD activity.
Immunohistochemical and Immunofluorescent Staining of
Fixed Tissues and Skin Fibroblast
Formalin-fixed, paraffin-embedded sections of cerebellum, mus-
cle, and liver from patient 1 were provided by the Department
of Pathology, Children’s Hospital of Alabama. Sections from the
same tissues from a 14-year-old boy who died of sudden cardiac
failure were selected from the files of the Department of Pathol-
ogy, Children’s Hospital of Pittsburgh. Five-micrometer sections
were cut at regular intervals and were mounted on glass slides.
Immunohistochemical staining was performed as described else-
where, with minor modification, with use of ACAD9, VLCAD,
LCAD, and MCAD antibodies at dilutions of 1:200–300.12 Stain-
ing was performed using the avidin–biotinylated peroxidase com-
plex (ABC) method (Vector Laboratories), was visualized by per-
oxidase substrate and 3,3-diaminobenzidine (DAB), and was
counterstained with hematoxylin.
Human cerebellum sections were reacted with 1:200 dilution
goat antiserum to the high-affinity aspartate/glutamate trans-
porter (EAAT4 [Molecular Probes]) and rabbit anti-ACAD9 anti-
bodies and were visualized with Alexa Fluor 680–conjugated don-
key anti-goat and IRDye 800CW–conjugated donkey anti-rabbit
immunoglobulin G (IgG) (HL [Rockland Immunochemicals]) at
a 1:5,000 dilution. The immune signals were detected with the
LI-COR Odyssey (42-mm resolution and 1-mm offset at the highest
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quality capture settings), in accordance with the manufacturer’s
instructions. For human liver sections, goat anti-human alpha-
1-antitrypsin (a-1-AT [Fisher Scientific]) was used as a control
antibody. For human lung sections, mouse anti-human MUC1
antibody (kindly provided by Dr. Joseph Pilewski, University of
Pittsburgh) was used as a control antibody. Human fibroblasts
were fixed with 4% formaldehyde on coverslips and were incu-
bated with primary antibody and fluorescent-labeled secondary
antibodies, in accordance with the manufacturer’s recommen-
dation, and were then visualized as described above.
Promoter Analysis
ACAD9 DNA fragments were amplified by PCR from control
and patient genomic DNA, starting at coding nucleotide position
50 and containing increasing lengths of 5′ untranslated se-
quence to nucleotide positions 264, 380, and 590. Frag-
ments were cloned upstream of the firefly luciferase reporter gene
in the promoterless pGL3-Basic plasmid (Promega) and were
confirmed by DNA sequencing. Transfection experiments in
HepG2 cells were performed as described elsewhere.13 A consti-
tutive reporter vector was cotransfected as a control. Cells were
lysed 48 h after transfection, and 20 ml of cell lysate was used for
a luciferase reporter assay with a Dual Luciferase Assay kit (Pro-
mega), in accordance with the manufacturer’s instructions. Light
intensity was measured by a Monolight 2010 luminometer for
10 s after manual reagent injection. All transfections were per-




Case report.—A 14-year-old boy presented with a Reye-
like episode triggered by ingestion of aspirin during a mi-
nor viral illness. Initial laboratory evaluation revealed a
markedly elevated plasma ammonia concentration (1700
mmol/liter; reference range 9–33 mmol/liter) and elevated
results from liver function tests: aspartate aminotransfer-
ase (AST) was 3,355 U/liter (reference range 15–40 U/liter),
alanine aminotransferase was 2,488 U/liter (reference
range 10–45 U/liter), and prothrombin time was 23.6 s
(reference range 10.6–12.6 s). Plasma glucose findings
were normal. His serum salicylate level was 23.2 mg/dL
(therapeutic range 2.8–20 mg/dL). Results of additional
laboratory evaluation were remarkable for a serum lactate
level of 10.8 mmol/dL (reference range 0.7–2.1 mmol/li-
ter), lactate dehydrogenase level of 15,394 U/liter (refer-
ence range 360–730 U/liter), creatine kinase level of 2,824
U/liter (reference range 30–150 U/liter), and creatine ki-
nase, muscle, and brain subunit levels of 9.5 ng/ml (ref-
erence range 0.0–5.0 ng/ml). Results from multiple viral
studies were negative. Acute hemodialysis was instituted,
and, after 3 d in the hospital, his ammonia level had de-
creased to 158 mmol/liter. In spite of this, the child re-
mained unresponsive, and a head CT scan showed diffuse
cerebral edema with tonsillar herniation. Neurologic ex-
amination confirmed brain death, and support was
discontinued.
Autopsy report.—Findings on autopsy included diffuse
hepatic microvesicular steatosis and some macrovesicular
steatosis, which were interpreted as being consistent with
Reye-like syndrome. Brain findings were notable for gen-
eralized edema with diffuse ventricular compression, acute
left tonsillar herniation, and diffuse multifocal acute dam-
age in the hippocampus. In addition, some abnormalities
consistent with nonacute changes were seen. These in-
cluded a subacute right cerebellar hemispheric infarct
measuring ∼2.5#3.5 cm and a moderate-to-severe reduc-
tion in the number of neurons in neocortex, cerebellum,
and hippocampus compared with age-matched controls,
even in areas not affected by acute damage. Liver and
muscle samples were rapidly frozen for additional bio-
chemical evaluation. Activities of electron transfer–chain
complexes were normal in muscle (Center for Inherited
Disorders of Energy Metabolism, Cleveland), and no de-
letions, duplications, or depletion or point mutations were
detected in mtDNA isolated from patient muscle and liver
(Horizon Molecular Medicine, Atlanta).
Patient 2
Case report.—The patient is a 10-year-old girl who ini-
tially presented with fulminant liver failure at age 4 mo.
Her blood glucose level at that time was lower than the
detectable range, and the AST was 1100,000 U/liter. She
had a rapid and effective response to intravenous glucose
therapy, and results from her prothrombin time and liver
function tests were back to near normal by the time she
was discharged. A head CT scan showed a small area of
low attenuation in the right inferior basal ganglia, inter-
preted as representing either prominent perivascular
space or old lacunar infarct. Results from extensive viral
studies were all negative. Findings from mtDNA mutation
and deletion screening from blood showed no abnormal-
ity. She continued to have recurrent episodes of hepato-
cellular dysfunction with hypoglycemia, usually triggered
by viral infections, as summarized in table 1. The acute
episodes have become less severe as she has aged. She
has also been noted to have a persistently low platelet
count (hovering near 120#109/liter) suggestive of chronic
thrombocytopenia.
Patient 3
Case report.—The patient was a 4.5-year-old girl with
cardiomyopathy and dilated left ventricle, whose family
history included a sibling who died of cardiomyopathy at
age 22 mo. During an acute illness at age 18 mo, she was
first given a diagnosis of severe left ventricular dysfunc-
tion. Hepatomegaly was also present. Her initial blood
glucose level was !20 mg/dl, and her plasma carnitine
level was 67 mM (reference range 25–79 mM), with a free
carnitine level of 16.3 mM (reference range 21–68 mM) and
a markedly elevated esterified fraction of 50.7 mM (refer-
ence range 2–7 mM). A defect in mitochondrial fatty acid
oxidation was suspected, but a specific diagnosis was not
made. She subsequently developed a pattern of recurrent
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17 mo 1,250 17,150 3.1/2.3 98.1
18 mo 637 18,400 4.3/3.1 81.7
3 1/2 years 684 13,720 3.0/1.8 35.2
5 10/12 years 1,031 5,730 3.7/2.6 19.6
6 11/12 years Normal 652 Normal Normal
9 years Normal 162 Normal Normal
a Reference range: 367–805 U/liter.
b Reference range: 20–40 U/liter.
c Reference range: total, 0.1–0.9 mg/dl; direct, 0.0–0.3 mg/dl.
d Reference range: 8.4–12.0 s.
rhabdomyolysis with intercurrent illness, with total cre-
atine phosphokinase level during acute episodes usually
rising to 11,000–13,000 U/liter (reference range 0–200 U/
liter). On carnitine supplementation, she had persistent
neurologic deficits with abnormal gait and clumsiness,
muscle weakness, and hepatomegaly with acute episodes.
She died of congestive heart failure at age 4.5 years. Au-
topsy revealed a dilated cardiomyopathy with prominent
liver necrosis.
Metabolic Evaluation of Patients
Measurement of urine organic acids in patient 1 showed
grossly elevated lactate and ketones with dicarboxylic and
hydroxydicarboxylic acids. Unsaturated species and 3-hy-
droxysebacic acid were the most prominent compounds
reported. The acylcarnitine profile from a postmortem
liver extract from this patient showed elevated long-chain
saturated and unsaturated species (Center for Inherited
Disorders of Energy Metabolism, Cleveland) (table 2). This
pattern was not characteristic of any known disorder of
mitochondrial b-oxidation but was strikingly similar to
the substrate-utilization profile of ACAD9; most notably,
C18:1 and C18:2 carnitine species, corresponding to the
optimal substrates of ACAD9, were markedly elevated.4,5
The acylcarnitine profile from postmortem muscle extract
from the patient exhibited a similar pattern of metabolites
(not shown). Additionally, several short branched-chain
species were present in a nonspecific pattern typical of
Reye syndrome.14 Blood acylcarnitine analysis was not per-
formed before death, and no postmortem blood, urine, or
other bodily fluid samples were available for study. To as-
sess overall mitochondrial b-oxidation, patient fibroblasts
were analyzed for production of acylcarnitine species after
incubation with tritium-labeled palmitic acid (C16; 16-
2H3-palmitic acid) and deuterium-labeled oleic acid (C18:
1; 9, 10-2H2-cis-9-C18:1) by the Institute of Metabolic Dis-
ease, Baylor University Medical Center, in accordance with
their standard clinical testing protocols. No abnormalities
were seen, except for a somewhat mild suppression of the
whole metabolite spectrum.
Blood glucose levels in both patients 2 and 3 were below
the detectable range at their initial presentation. No fur-
ther episodes of hypoglycemia were reported in patient 3,
whereas a rapid drop in blood glucose level was reported
during two subsequent acute episodes in patient 2 through
age 2 years. Urine organic acid profiles of both patients 2
and 3 during acute illness showed hypoketotic dicarbox-
ylic aciduria with prominent unsaturated species, as well
as 3-hydroxyadipic, 3-hydroxysuberic, and 3-hydroxyse-
bacic acids. Urine acylglycine levels were normal in both
patients during acute illness, excluding most of the known
fatty acid oxidation disorders. The total plasma carnitine
level in patient 2 fell during illness but recovered to a
normal level without supplementation, and her plasma
acylcarnitine profile was normal. Interestingly, the urine
acylcarnitine profile of both patients 2 and 3 was notable
for elevation of acetylcarnitine in the face of normal or
reduced ketones. Fatty acid oxidation studies of fibroblasts
from patient 2 showed reduced oxidation of myristate
(16.1 pmol/min/mg protein; reference range [SD]
26.53.0) and palmitate (33.4 pmol/min/mg protein; ref-
erence range 62.716.1), in agreement with the presence
of a defect in long-chain fatty acid oxidation, but findings
from assays of long-chain 3-hydroxyacyl-CoA dehydro-
genase (LCHAD), long-chain 3-ketothiolase, short-chain
3-hydroxyacyl-CoA dehydrogenase, short-chain 3-keto-
thiolase, and carnitine palmitoyl transferases 1 and 2 were
normal (reported by Dr. Michael Bennett, Children’s Hos-
pital of Philadelphia). In addition, DNA sequencing of the
entire coding region of short-chain 3-ketothiolase, 3-
hydroxymethylglutaryl-CoA synthase, VLCAD, MCAD,
LCAD, and selected exons of long-chain 3-hydroxyacyl-
CoA dehydrogenase from patient 2 failed to identify a
mutation (reported by Dr. Arnold Strauss, Vanderbilt
School of Medicine). No frozen blood or tissue samples
were available from patient 3 for study.
Results
Biochemical Comparison of Purified Recombinant ACAD9,
VLCAD, and LCAD
All three patients had biochemical findings suggestive of
an unknown long-chain fat metabolism defect. To further
pursue this finding, we first sought to better characterize
the enzymatic properties and tissue distribution of the
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C12 .58 (.16–.23) 6.5 (.07–.81)
C14 1.47 (0) 20.25 (.0–.92)
C16 5.38 (.79–1.54) 62.00 (.30–5.32)
C16:1 3.07 (0–.13) 32.00 (.00–2.50)
C18 5.86 (.5–1.9) 41.00 (.24–3.09)
C18:1 14.6 (.23–1.67) 139.50 (.64–35.59)
C18:2 3.84 (.34–1.8) 62.75 (.00–15.31)
a Laboratory reference range.
known long-chain ACADs. VLCAD, ACAD9, and LCAD
have all been purified from tissue or recombinant sources,
but reports on their enzymatic function have varied in
technique, making direct comparison of their catalytic
properties difficult. To facilitate this comparison, we ov-
erexpressed the mature forms of each in an E. coli system
and purified them to 195% homogeneity. The specific ac-
tivities of purified recombinant VLCAD, ACAD9, and
LCAD with palmitoyl-CoA as substrate were 13 U/mg pro-
tein, 1.2 U/mg protein, and 0.9 U/mg protein, respectively,
as measured by the ETF fluorescence-reduction assay. All
three purified enzymes had similar specificity for the sat-
urated and unsaturated substrates used predominantly for
energy generation, such as C16:0-CoA, C16:1-CoA, C18:
0-CoA, and C18:1-CoA (fig. 1a). In contrast, ACAD9 dif-
fered significantly from VLCAD in the use of polyunsat-
urated substrates not primarily used for energy, especially
C22:6-CoA, and LCAD is the only one of three enzymes
that uses long- and branched-chain substrates, including
THC-CoA (fig. 1a).
Tissue Expression of Long-Chain ACADs
Quantitative real-time PCR was used to measure the ex-
pression of each long-chain ACAD gene, along with MCAD
and SCAD, in 21 adult and fetal human tissues. The ex-
pression of two housekeeping genes (GUSB and the gene
for 18S rRNA) was used as an internal control. Figure 1b
and 1c show expression of ACADs normalized to GUSB;
the pattern was unchanged when 18S rRNA expression
was used as control instead (not shown). In muscle, a tis-
sue with a high rate of b-oxidation, all of the ACADs tested
were highly expressed. The expression levels of VLCAD,
MCAD, and SCAD were 34, 4.9, and 17 times that of GUSB,
respectively, whereas the expression levels of ACAD9 and
LCAD were nearer to that of GUSB, suggesting that ex-
pression of the long-chain ACADs may be differentially
regulated. It has been reported that significant levels of
VLCAD nonsense transcripts exist in cells and in most
human tissues—for example, transcripts with retention of
intron 10 that introduces a premature stop codon into the
message.15 Such a high level of nonsense VLCAD message
may be associated with post-transcriptional regulatory
functions.16 The expression level of each ACAD in each
tissue is compared with its expression level in muscle, and
all are shown in figure 1b and 1c. VLCAD, MCAD, and
SCAD were the most highly expressed in muscle and heart
(fig. 1c), tissues that use long-chain fatty acids for 85% of
their energy, which is consistent with the function of these
enzymes in energy homeostasis.1 Whereas the expression
pattern of ACAD9 overlapped VLCAD in muscle and heart,
ACAD9 was the only long-chain ACAD mainly expressed
in brain (fig. 1b). LCAD was the only long-chain ACAD
mainly expressed in kidney, lung, thyroid gland, and pros-
tate gland (fig. 1b). These tissues, along with human brain,
have high levels of lipid recycling and synthesis. LCAD
had higher expression in fetal than adult brain, a pattern
opposite of ACAD9 (fig. 1b).
Immunohistochemical staining in human muscle,
brain, and lung revealed that the protein distribution of
each of the enzymes followed their gene expression pat-
terns (fig. 2 and table 3). VLCAD staining was much stron-
ger than ACAD9 (fig. 2a and 2b) and LCAD (not shown)
staining in muscle, and the distribution of its staining was
different than that of ACAD9. The VLCAD staining pat-
tern was unevenly distributed, with the greatest signal in
slow-twitch muscle fibers (fig. 2a). In contrast, ACAD9 was
predominantly localized perivascularly (fig. 2b). Immu-
nohistochemical staining of normal human brain sections
with ACAD9 antibody revealed a primary neuronal loca-
tion for ACAD9 (fig. 2d–2i). This included most neurons
of all five layers of frontal cortex (fig. 2d) and various
neurons in hippocampus, including all the cornus am-
monis regions and the dentate gyrus (fig. 2e and 2f).
ACAD9 staining was particularly strong in the small gran-
ular neurons of the dentate gyrus, and the neurons of the
CA4 region (fig. 2f) gave a much stronger signal than those
in the CA1 region (fig. 2e). In human cerebellum, ACAD9
decorated Purkinje neurons and dentate nucleus. It also
was present in neuronal dendrites in the granular layer,
very likely in granular neurons (fig. 2c, 2g, and 2i). Thus,
the distribution of ACAD9 is distinct for specific subgroups
of neurons. The staining pattern of ACAD9 in cerebellum
cortex is a diffuse punctate pattern extending to neuronal
dendrites, which is characteristic for mitochondrial stain-
ing (fig. 2c). Staining of this region with a VLCAD antibody
gave no signal (not shown), consistent with previous lit-
erature reports.12 The distribution of long-chain b-oxida-
tion enzymes, including VLCAD, ACAD9, LCAD, and
LCHAD, is summarized in table 3.
Enzymatic and immunoinactivation studies confirmed
that long-chain ACAD activity in human cerebellum cor-
tex was predominately ACAD9 (figs. 1d and 3). In contrast,
ACAD9 and VLCAD activities were equally represented in
liver, whereas nearly all of the long-chain ACAD activity
in muscle was from VLCAD (fig. 1d). LCAD antigen was
the only one of the three long-chain ACADs identified in
lung, where it colocalized with a lung epithelial cell mar-
ker (MUC1 protein) in bronchial epithelium and through-
out the alveolar septae (fig. 2j-2m). It was especially abun-
dant in the alveolar type II epithelial cells responsible for
synthesizing surfactant (fig. 2j and 2k).17,18
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Figure 1. Comparison of activity, expression, and tissue localization of VLCAD, ACAD9, and LCAD. The specific activity of VLCAD,
ACAD9, and LCAD, as measured with palmitoyl-CoA, was 13, 1.2, and 0.9 U/mg, respectively (a). All substrates used are described in
the “Methods” section. b and c, Expression of mRNA of ACAD9 and LCAD (b) and VLCAD, MCAD, and SCAD (c), measured in 21 human
tissues by real-time RT-PCR and compared with the relative level of expression in muscle. The ratio of expression of VLCAD, ACAD9,
LCAD, MCAD, and SCAD in muscle to the housekeeping gene GUSB was 34, 1.0, 0.4, 4.9, and 17.1, respectively. d, Immunoinactivation
of ACAD activity in human liver, muscle, and brain, measured with C18:0-CoA as substrate. VLCAD antibodies inactivated 32%, 100%,
and 0% of the activity measured in the mitochondrial membrane fraction of human liver, muscle, and brain, respectively, whereas ACAD9
antibodies inactivated 41%, 0%, and 100% in these same tissues.
ACAD9 Promoter Analysis and Functional Studies
The distinctive tissue-distribution pattern of expression of
the long-chain ACADs led us to further study the regu-
latory factors for the ACAD9 gene. The computer pro-
grams PROSCAN and TFSEARCH were used to evaluate the
5′ region of the ACAD9 gene (2 kb of sequence covering
the 5′ UTR of the ACAD9 gene, exon 1, intron 1, and exon
2) for possible promoter sequences, including major tran-
scription-factor binding sites. The minimal promoter re-
gion predicted for the ACAD9 gene (starting at position
264) is shown in figure 4a. The transcriptional start sites
www.ajhg.org The American Journal of Human Genetics Volume 81 July 2007 93
Table 3. Labeling of Brain Sections with
Antibodies to ACAD9, LCHAD, LCAD, and VLCAD
Cerebral Region ACAD9 LCHAD LCAD VLCAD
Frontal cortex:
Pyramidal cells    
Endothelial cellsa    
Hippocampus:
CA1    
CA4    
Granular layer    
Cerebellum:
Purkinje    
Granular layer    
Dentate nucleus    
a ACAD9-specific staining was not seen in the endothelial
cells in frontal cortex; however, it was present in the en-
dothelial cells in the deep white matter of cerebellum.
Figure 2. Immunohistochemical and immunofluorescent staining of normal human brain and muscle sections with ACAD9 antisera
and human lung sections with LCAD antisera. a and b, Immunohistochemical staining of human muscle with VLCAD (a) and ACAD9 (b)
antibody visualized with DAB (brown), counterstained with a blue nuclear stain. c, Diffuse and punctate pattern of ACAD9 staining,
extending to neuronal dendrites of Purkinje cells. The nucleus of Purkinje and granular neurons does not stain with ACAD9 antibodies
visualized with fluorescent secondary antibody (white). d–i, Normal human brain section immunostained with ACAD9 antibody and
visualized with DAB (brown). All sections are counterstained with a nuclear stain (blue). d, Neurons of human neocortex. e, Neurons
in the CA1 region of normal human hippocampus showing relatively weak ACAD9 staining. f, Neurons in the CA4 region and granular
neurons of hippocampus. g, Cerebellar cortex, including Purkinje neurons, their dendrites, and neurons in the granular layer, showing
relatively strong ACAD9 staining. h, Absence of ACAD9 staining in cerebellar white matter. i, Strong ACAD9 staining in dentate nucleus
in the deep white matter of cerebellum. j and k, Normal human lung sections stained with LCAD (j) or the marker protein MUC1 (k) (a
membrane protein, specific to human alveolar septae) antibody and visualized by fluorescent secondary antibodies, LCAD (j, red) and
MUC1 ( k, green), colocalizing to type II alveolar epithelial cells (white arrow), as described in the “Methods” section. l and m, LCAD
antibodies specifically staining bronchial epithelium and the alveolar septae of normal human lung tissue (l). At high magnification,
the staining of LCAD in bronchial epithelium (m) shows a diffused punctate pattern consistent with mitochondrial staining.
1 and 2 (TSS1 and TSS2) were inferred from the consensus
of the 5′ end of EST tags in the dbEST database, using the
BLAST tool in combination with PCR analysis. TSS2 ap-
pears to be a major transcriptional start site, since it
matches most of the 5′-end EST tags; however, there are
also a number of 5′-end EST sequences with TSS1 as the
start site. PCR primers close to either TSS site efficiently
amplified full-length ACAD9 coding cDNA. Three eukar-
yotic expression vectors were constructed to test the abil-
ity of the sequences around this region to act as a promoter
(fig. 4c). Varying lengths of 5′ UTRs of the ACAD9 gene
were cloned upstream of a promoterless luciferase reporter
gene, and the level of expression was compared with that
of a constitutive reporter gene on a control vector after
cotransfection into the human hepatoma cell line HepG2.
ACAD9 sequences including nucleotides 590 to 50
(p1A9) and 264 to 50 (p3A9) both led to high levels
of expression of the reporter gene, whereas a fragment
from 380 to 50 (p2A9) gave very low expression. The
growth of all cultures after transfection was similar. This
confirms that the predicted minimal promoter region con-
tains the major regulatory elements for expression of
ACAD9.
Phylogenetic alignment of the ACAD9 promoter region
revealed two evolutionarily highly conserved regions,
each with duplicated sequences homologous to nuclear
respiratory factor 1 (NRF-1) and cAMP-responsive element
transcription-factor binding sites (CREB) (fig. 4b). Scan-
ning of 5 kb of the 5′ UTR of both human and mouse
ACAD9 genes, with use of the online software NHR SCAN,
failed to identify a putative direct repeat site 1 (DR1) bind-
ing site for the peroxisomal proliferation-activated recep-
tors (PPARs). In contrast, multiple DR1 sites are present in
the promoter region of the VLCAD gene and in all other
known human and mouse ACAD genes. Thus, it appears
that expression of the ACAD9 gene is independent of
PPARa but, rather, is controlled by NRF-1 and CREB, im-
portant regulators of the genes involved in mitochondrial
biogenesis and those for most respiratory-chain enzyme
subunits.19,20
Stimulation of various human cell lines with cytokines
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Figure 3. Immunoinactivation of purified ACAD9 protein. Serial dilutions of purified rabbit anti-ACAD9 IgG were used to inactivate
1.5 mg of purified recombinant ACAD9 or VLCAD. Reactions were performed in the presence of 0.5 mg/ml of BSA and 5% glycerol. After
incubation with antibody, reactions were precipitated with S. aureus protein A–conjugated Sepharose beads, and the remaining ACAD
activity was measured with the ETF fluorescence-reduction assay. The data plotted represent the average of duplicate measurements.
a, Twenty to 80 mg of ACAD9 antibody incubated with purified ACAD9. The Y-axis shows the relative activity compared with enzyme
without antibody treatment. b, Up to 160 mg of ACAD9 antibody incubated with purified VLCAD protein and plotted as was that in
panel a.
has been shown to down-regulate retinoid X receptor
(RXR)/PPAR–dependent genes and to up-regulate NRF-1–
controlled genes.21 Addition of interferon-a (INF-a) or a
combination of both INF-a and tumor necrosis factor-a
(TNF-a) to cultured fibroblasts led to significant reduction
of ACAD activity measured with C18-CoA activity in cells
from patient 2 but not in those from control cells (table
4). In contrast, activity measured with C12-CoA, metab-
olized primarily by MCAD (the expression of which is
regulated by multiple independent elements besides RXR/
PPAR22,23), was unaltered with cytokine treatment. Thus,
defective long-chain ACAD activity can be detected in
ACAD9-deficient patient (patient 2) fibroblast on cytokine
simulation, since down-regulation of VLCAD in patient 2
cells was apparently not compensated by induction of
ACAD9 activity, as it was in controls.
Two ACAD9 mRNA and Protein Isoforms Exist in Cells
Subcellular localization studies of ACAD9 protein in hu-
man skin fibroblasts revealed that it was present not only
in mitochondria but also in the cytoplasm and nucleus,
suggesting the presence of so-called moonlighting func-
tions for this protein24 (figs. 5c–5e and 6). This was also
seen in hepatocytes (data not shown) but not in most of
the neurons in the cerebellum (fig. 2c). We were able to
confirm the existence of two protein forms in fibroblast
and liver lysate that differed by ∼10 kDa in molecular mass
(figs. 5a, 5b, and 6). One form corresponds to the previ-
ously recognized mitochondrial enzyme (64.8 kDa). The
other form corresponds in size to the predicted protein
product encoded by an alternative mRNA species identi-
fied in the public databases that appears to be generated
by alternative splicing of ACAD9 message (ACAD9 variant
a in fig. 7a) and eliminates the mitochondrial targeting
signal. Subcellular fractionation experiments with fibro-
blast lysate showed that the 76-kDa protein was present
in both cytoplasm and nuclear (c/n) fractions (fig. 6b).
Both ACAD9 protein species react specifically with our
ACAD9 antibody, as shown by immunocompetition ex-
periments (fig. 6a).
The ACAD9 variant a (GenBank accession numbers
CR613592 and BX415793) (aAugust05 [AceView]) mRNA
differs from variant b (GenBank accession number
NM_014049) (bAugust05 [AceView]) by the presence of an
alternative exon 1a at the 5′ terminus, one alternative exon
18 resulting from differential splicing, and four additional
exons (19–22) in the 3′ UTR (fig. 7a). At least 33 human
ESTs containing exon 1a exist in dbEST. However, this
region is conserved only in primates and not in other
mammals. Alternative exon 1 could be amplified by PCR
from human fibroblast cDNA, substantiating its existence
in vivo (fig. 7b, lane 2). A number of human ESTs in the
public database also support the existence of the alter-
native exons in the 3′ UTR in some transcripts; however,
the combination of exons and the alternative splicing of
exon 18 is variable. Therefore, the exact sequence of the
3′ UTR of ACAD9 variant a remains unclear. This may
explain the absence of the second species when full-length
ACAD9 is amplified from cDNA (fig. 7b, lane 6, and 7c,
lane 2), since the 3′ amplification primer likely sits in a
region that varies between variants a and b. Analysis with
PSORT II predicts that variant a most likely localizes to
the cytoplasm (43%) or nucleus (30%). A putative nuclear
targeting sequence (PRERKEV) is encoded by alternative
exon 1a and replaces the mitochondrial targeting se-
quence in variant b. However, the translation start codon
predicted for this transcript is a CTG instead of an ATG,
a codon rarely used in mammals. Further investigation of
the alternative ACAD9 protein is necessary to understand
its molecular origin. Interestingly, intron 21 and exon 22
of ACAD9 variant a overlap an unrelated gene, KIAA1257,
on the opposite DNA strand. Thus, it is possible that ex-
pression of ACAD9 variant a can also be regulated by the
expression of the KIAA1257 gene.
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Figure 4. Promoter function of the ACAD9 gene and its putative regulatory pathway. a, Sequence of the human ACAD9 gene promoter
region, as predicted by computational analysis. The transcriptional start sites (TSS1 and TSS2) were inferred from the consensus of the
5′ end of EST tags in dbEST in combination with PCR analysis. b, Two conserved nucleotide blocks that match the consensus sequences
for NRF-1 and CRE transcription-factor binding sites. The dotted line indicates the invariant nucleotides in the recognition sites among
different species. The NRF-1 and CRE sites are duplicated in all primates. c, A series of fragments containing increasing lengths of 5′
UTR from the ACAD9 gene, inserted upstream of a firefly luciferase reporter gene (Luc) in the promoterless pGL3-basic vector. The TAAG
insertion identified in the patient is shown as a vertical bar in exon 1. d, The promoter-luciferase fusion constructs, transfected into
HepG2 cells along with an internal control. The luciferase activity is presented as the mean and SD from at least three independent
experiments, as described in the “Methods” section. The 4-bp insertion was introduced in plasmid p3A9 (e), and the activities were
measured as were those in panel d.
ACAD9 Activity and Antigen Is Reduced or Deficient in
Patient Cells
All of the apparent ACAD9-deficient patients exhibited
marked abnormalities in ACAD9 protein (fig. 5). In con-
trast, VLCAD and MCAD antigen was comparable to con-
trol in all patient samples (fig. 5l–5n, lanes 3 and 4 for
patient 3; data not shown for patient 1 and 2). LCAD
antigen was minimal in both patient and control fibro-
blast and liver and was normal in patient muscle (not
shown). Patient 3 lacked all identifiable ACAD9 antigen
(fig. 5l–5n, lane 2). Although a minimal amount of ACAD9
antigen was detected in samples from patients 1 (fig. 5a,
5i–5k, and 5o–5q) and 2 (fig. 5b and 5f–5h), it was not
likely to be enzymatically active, since none was appro-
priately targeted to mitochondria (fig. 5f–5k). Instead, the
residual ACAD9 protein in patient 1 was predominantly
cytoplasmic. Most detectable ACAD9 antigen in patient 2
localized to the perinuclear region, with a much lower
signal in cytoplasm.
VLCAD has been demonstrated elsewhere to account
for nearly all of the activity toward palmitoyl-CoA in crude
fibroblast extracts.25 In keeping with this finding, both
patients 1 and 2 had normal long-chain activity in fibro-
blasts, whereas a known VLCAD-deficient cell line had no
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Table 4. ETF Fluorescence
Reduction Assay of Patient 2 and






C12 C18 C12 C18
Untreated 1.42 1.20 1.59 1.66
INFa 1.43 1.18 2.14 NDb
INFaTNFa 1.68 1.13 2.01 NDb
a All the activity data are averages
of measurements from two independent
experiments.
b ND p not detectable.
detectable activity (tables 4 and 5). In contrast, VLCAD
and ACAD9 were present in equal proportions in liver
mitochondrial membrane preparations (fig. 1d). Consis-
tent with this, VLCAD-deficient patients and VLCAD-null
mice have previously been shown to have a 50% reduction
in palmitoyl-CoA activity in liver.25,26 A frozen liver sample
available from patient 1 had 46% ACAD activity measured
with palmitoyl-CoA as substrate, as compared with a con-
trol sample (table 5), and reduction of C16 activity in
mitochondrial membrane fraction of patient liver was
170% (not shown), but sample size did not permit addi-
tional immunoinactivation experiments. However, fibro-
blasts from patient 1 had normal activity measured with
palmitoyl-CoA as substrate, indicating normal VLCAD ac-
tivity. Thus, the reduction in activity in patient liver must
be due to loss of ACAD9. No liver tissue from patient 2
was available for assay.
Abnormalities of ACAD9 in the Brain of Patient 1
The autopsy report of the brain of patient 1 described
mild, apparently chronic abnormalities, with a signifi-
cantly reduced number of neurons in the gray matter of
hippocampus, neocortex, and cerebellum, but it was not
clear if this was due to a developmental or degenerative
defect. This distribution matches that of the expression
pattern of ACAD9 protein in the CNS. Our immunoflu-
orescence staining of ACAD9-specific antigen in patient
cerebellum cortex tissue confirmed that ACAD9 protein
was almost absent (fig. 5o–5t). We therefore performed
glial fibrillary acid protein (GFAP) staining (a marker of
gliosis) of various brain sections from patient postmortem
brain, including neocortex, hippocampus, and cerebel-
lum. GFAP staining in patient gray matter was similar to
that in control samples and does not support the presence
of chronic degeneration (not shown). Interestingly, a mild
increase of leukocyte common antigen (LCA) staining was
seen in perivascular cells around the blood vessels in the
white matter of the centrum semiovale (fig. 8a and 8b).
LCA staining was, however, normal in sections of the gray
matter and leptomeninges from neocortex. Morphologi-
cally, the staining cells were a mixture of macrophages
(including some hemosiderin laden) and lymphocytes.
Similar inflammatory cell infiltration was seen in the
white matter of brain stem from the patient but not in
hippocampus or cerebellum, where the damage from his
acute clinical course was the most severe. Such inflam-
matory cell cuffing is not normal in the brain of a 14-
year-old.
Molecular Analysis of ACAD9 mRNA and Genomic DNA
Full-sized ACAD9 message could easily be amplified from
control liver and fibroblast mRNA but not from cDNA
made from fibroblast mRNA from either patient 1 or 2 (fig.
7b and 7c) or liver mRNA from patient 1. When primers
corresponding to subsections of the ACAD9 message were
used for amplification, two dominant species were iden-
tified in cDNA from patient 1 that were smaller than the
expected size for normal message (fig. 7b). Direct sequenc-
ing of each fragment revealed that one was missing se-
quences corresponding to exons 2–5, whereas the other
was missing exon 12–17 sequences (fig. 7e). Additional
minor species were also occasionally seen in repeat ex-
periments, all of which also contained absent exons (not
shown). Misspliced RNA species were also amplified from
cDNA made from patient 2 fibroblast mRNA, with a de-
letion of exon 3 found in the most prominent species.
Only paraffin-fixed tissue was available from patient 3,
and attempts to amplify DNA from it were unsuccessful.
All 18 exons, the intron-exon boundaries, and 650 bp
of 5′ UTR and untranscribed region of the ACAD9 gene
were amplified and sequenced from genomic DNA from
patients 1 and 2. A 4-bp insertion was found 44 bp up-
stream of the first ATG in one allele from patient 1 (fig.
7d, left). Only a minimal signal corresponding to this in-
sertion was visible when fragments amplified from cDNA
made from patient liver mRNA were directly sequenced,
suggesting a transcriptional defect in this allele (fig. 7d,
right). Introduction of this 4-bp insertion into a p3A9 pro-
moter construct led to 75% reduction of expression of a
reporter gene (fig. 4e). This insertion is not found in
dbSNP, and screening by PCR of genomic DNA from 244
alleles from ethnically matched controls identified only
one containing the 4-bp TAAG insertion. There is only
one report of this insertion in 1330 independent ACAD9
cDNA sequence entries in the human EST database (BI
911835.1), and it appears in a sample made from pooled
human leukocytes from an unknown number of individ-
uals. In addition, the insertion is reported in the Hela cell
line (DA 567380).
Although a number of intronic sequence variants were
identified near intron-exon boundaries in both patients 1
and 2 (table 6), none affect canonical splicing sequences,
nor did Southern blotting reveal a large deletion in either
patient’s ACAD9 gene (not shown). Thus, the origin of the
apparently misspliced transcripts in mRNA from patients
1 and 2 remains undetermined. Variations in exon se-
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Figure 5. Subcellular location of ACAD9 protein. a and b, Western blot of fibroblast and liver lysate with anti-human ACAD9 antibodies.
One major band (M) in control samples (a, lanes 2 and 4; b, lane 2) co-migrated with purified recombinant mitochondrial ACAD9 (a,
lane 1; b, lane 1), and another was larger (c/n). Both forms were missing or reduced in patient samples (a, lanes 3 and 5; b, lane 3).
VLCAD-deficient fibroblasts (V) (a, lane 2) and normal human fibroblast (N) (b, lane 2) or postmortem liver (N) (a, lane 4) served as
controls. c–e, Immunofluorescent staining of normal fibroblasts with ACAD9 (c, green) and mitochondrial ATP synthesase (mATPase) (d,
red) antibodies, visualized by fluorescent secondary antibodies. The merged image (e) shows that the two proteins colocalize in part
(yellow). A green ACAD9 signal is seen in the nucleus (white arrow). Panels f–h and i–k are the same as panels c–e but use fibroblasts
from patients 2 and 1 (P2 and P1), respectively. l–n, Immunofluorescent staining of postmortem liver from patient 3 (P3) and a control
(C) with antibodies against ACAD9 (l, green) or liver-specific a1-AT (m, red), visualized by fluorescent secondary antibodies. The merged
signal is shown in panel n. ACAD9 (aA9) (lanes 1 and 2) staining is deficient in patient 3 (lane 2), but MCAD (aM) (lane 3) and VLCAD
(aV) (lane 4) staining are normal. o–t, Immunofluorescent staining of postmortem cerebellar cortex of patient 1 (P1) (o–q) and control
(r–t) with antibodies to the cerebellar cortex marker EAAT4 (o and r, red) or ACAD9 (p and s, green); the merged signal is shown in
panels q and t, in pseudocolored yellow. ACAD9 is prominent in control (s) but is absent in patient cerebellum (p). A white arrow
indicates ACAD9-specific staining of dentate nucleus in deep white matter of the normal control.
quences were also found in both patients. 379ArC (exon
4) and 1476CrT (exon 14) are common variants in dbSNP.
Both the 787TrC (exon 7) and g.40508GrA (exon 22) are
also present in dbSNP, but their population frequency has
not been determined. None of the sequence variants in
exons 4, 7, or 14 cause amino acid changes, and exon 22
is in the 3′ UTR. The sequence variant g.34927CrT in exon
20 of patient 1 is not present in dbSNP. However, since
exon 20 is also in the 3′ UTR, the effect of this private
sequence change remains unclear. Parental DNA was not
available for study from either family.
Discussion
This report presents the first cases of ACAD9 deficiency.
Although the patients have different phenotypes, the
spectrum of findings is similar to that seen in other
known long-chain fatty acid b-oxidation defects, in-
cluding VLCAD deficiency.1 The presentation of a Reye-
like episode after aspirin ingestion during a viral illness
has most frequently been reported in LCHAD-deficient
(HADHA [MIM 600890] and MCAD-deficient (ACADM
[MIM 607008] patients,27,28 but ACAD9 deficiency should
now be considered if other b-oxidation defects are not
identified. Cardiomyopathy is common in both VLCAD
and LCHAD deficiencies1 and was present in the pair of
ACAD9-deficient sibs described here. Fulminant liver fail-
ure was the most dramatic aspect of the case of patient 2
and is not typical of other b-oxidation disorders in the
absence of Reye syndrome. The incidence of cerebral
strokes in children and young adults is ∼2.5:100,000.29
Whereas a number of metabolic disorders are associated
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Figure 6. Immunocompetition and subcellular fractionation of ACAD9 antigen in human fibroblast lysate. a, Immunocompetition of
ACAD9 antigen in human fibroblast lysate by purified ACAD9 protein. Fifty micrograms of normal human fibroblast lysate or 40 ng of
purified ACAD9 protein were separated by SDS-PAGE and were transferred to a PVDF membrane. The membrane was then incubated with
ACAD9 antibodies (affinity purified) with and without an equal amount (mole/mole) of purified ACAD9 protein. Lanes 1 and 2 show
the reaction of fibroblast extract and purified ACAD9 with ACAD9 antibody. Lanes 3 and 4 show the same as do lanes 1 and 2, except
that the ACAD9 signals on the membrane are diminished when purified ACAD9 protein is included in the antibody-incubation mixture.
Arrows point to two ACAD9 protein species with different molecular masses. The band marked “mA9” corresponds in size to purified
mature mitochondrial ACAD9, whereas the other ACAD9 species (c/n A9) is ∼10 kDa bigger than mA9 and is of a size consistent with
the predicted cytosolic/nuclear form of ACAD9. Lane 5, Molecular mass markers. The two marked bands are b-galactosidase (94 kDa)
and albumin (66 kDa). b, Subcellular distribution of ACAD9 proteins in normal fibroblast extract. Fibroblasts were lysed by repeated
cycles of freezing and thawing, and the cytoplasmic fraction (lane 4) was separated from the nuclear/mitochondrial fraction (lane 3)
by centrifugation. Lane 2, Purified ACAD9. Protein markers in lane 1 are the same as those in panel a.
with stroke or strokelike episodes, they are rarely vascular
in nature in disorders of mitochondrial energy metabo-
lism.29 Patient 1 in this report had pathologic evidence of
a bona fide cerebellar vascular accident. On the basis of
histologic criteria, it is likely that the stroke dated to the
beginning of the patient’s acute illness. It is not clear
whether the stroke was directly related to his ACAD9 de-
ficiency or was secondary to his liver disease and coagu-
lopathy, though the latter was mild. Of note, a remote
infarct close to the brain-stem region also was identified
by magnetic resonance imaging scan in patient 2. Thus,
ACAD9 deficiency should be considered in unexplained
cerebrovascular stroke.
To better understand the differences in the physiological
functions of the long-chain ACADs, we compared the sub-
strate specificity and tissue-distribution pattern of ACAD9,
VLCAD, and LCAD. ACAD9 and LCAD were found to be
distinct from the other known ACADs involved in energy
production, including VLCAD, implicating them in other
metabolic pathways. C22:6-CoA was a preferred substrate
for ACAD9 but not for VLCAD. However, neither enzyme
had significant activity with C20:5-CoA as substrate (not
shown), indicating that ACAD9 shortens C22:6-CoA to
C20:5-CoA through a single cycle of b-oxidation. LCAD
was the only one of the three to have significant activity
with a variety of long, branched-chain substrates, includ-
ing THC-CoA, an intermediate in an alternative mito-
chondrial pathway for free bile acid synthesis implicated
in regulation of the cellular metabolic rate (fig. 1a).30 The
ability of ACAD9 to use the CoA esters of polyunsaturated
fatty acids such as C22:6 is consistent with the finding
that it is the predominant long-chain ACAD in human
cerebellum, a rich source of polyunsaturated fatty acids.
LCAD is the only long-chain ACAD mainly expressed in
human lung (in type 2 pneumocytes), thyroid, prostate
gland, and kidney. One possible role of LCAD in the lung
is in surfactant metabolism, since dipalmitoylphosphati-
dylcholine is the most abundant long-chain lipid in sur-
factant, synthesized predominantly in type 2 pneumo-
cytes. The functional difference among the three long-
chain ACADs and the identification of distinct VLCAD-
and ACAD9-deficient patients indicates that these en-
zymes cannot compensate for each other in vivo.
The overlap in substrate use by the long-chain ACADs
presents potential challenges in distinguishing deficient
patients on the basis of metabolic profiles, since deficient
patients may accumulate similar intermediate metabolites
from long-chain fatty acid b-oxidation. Moreover, many
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Figure 7. Molecular analysis of ACAD9-deficient patients. a, ACAD9 consisting of 22 exons and generating two predominant molecular
species through alternative splicing. The schematic drawing illustrates that the basic ACAD domain structure of both translated proteins
is conserved (ACDN, ACDM, and ACDC); however, in one, a nuclear targeting signal (N) is substituted for the mitochondrial targeting
signal (M). This variant message also contains a longer exon 1, giving a longer N-terminus (U) and a shorter exon 18 along with
additional exons 19–22. b and c, Amplification of ACAD9 sequences from control (C), patient 1 (P1), and patient 2 (P2) mRNA. PCRs
with control fibroblast cDNA as template readily amplified full-length ACAD9 coding sequences (b, lane 6; c, lane 2 ) and overlapping
subfragments (b, lane 2, exons 1–7; b, lane 4, exons 6–18). Full-length message (exons 1–18) could not be amplified from mRNA either
from patient 1 (b, lane 7) or patient 2 (c, lane 3). Shorter-than-expected fragments were amplified from patient 1 cDNA (b, lane 3,
exons 1–7; lane 5, exons 6–18). d, Sequence of ACAD9 UTR from genomic DNA and cDNA. Sequencing chromatograms of genomic DNA
from patient 1 (left panel) identified a dual pattern due to a 4-bp insertion. Patient cDNA in that region showed only the normal
sequence, without the insertion (right panel). e, Diagrams of ACAD9 species amplified from cDNA from patient 1. One consisted of exon
1 joined to exon 6 (a), whereas the other consisted of exon 11 jointed to exon 18 (b).
of these long-chain intermediates are known to be toxic
and may lead to similar clinical presentation, such as car-
diomyopathy, as seen in our patient 3 as well as in patients
with other long-chain fatty acid oxidation defects.31,32 Dif-
ferences in tissue distribution of ACAD9 and VLCAD pro-
vide a method to distinguish ACAD9 or VLCAD deficiency
by direct enzymatic assay of tissue samples, though this
would require an invasive procedure.
One of the major functions of mitochondrial b-oxida-
tion is in maintenance of energy homeostasis. Loss of this
function in patients with genetic defects in b-oxidation
triggers fasting or stress-induced metabolic crises that can
usually be treated by providing patients with an alterna-
tive energy source.1 Another major function of mitochon-
drial b-oxidation is to recycle carbons from a variety of
long-chain fatty acids for lipid synthesis.6 Little is known
about the effect of disruption of this process on the path-
ogenesis of symptoms in defects of b-oxidation, and it
may, in part, explain the features of these disorders that
respond poorly to treatment with alternative energy
sources such as neurological dysfunction and acute re-
spiratory distress syndrome.33,34 These symptoms are not
reported in patients with deficiencies in VLCAD or
MCAD but are seen in patients with deficiencies in
LCHAD and mitochondrial trifunctional protein (MTP
[MIM 609015]).33,34
ACAD9 is the only ACAD identified to date that is
highly expressed in human brain and is mostly localized
to a subpopulation of neurons that are coincident with
LCHAD/MTP (table 2), most notably in the cerebellum.
The role of mitochondrial b-oxidation of long-chain fatty
acid in the human CNS has long been controversial. Neu-
ropathological problems are uncommon in patients with
defects of fatty acid oxidation (except for LCHAD/MTP
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Table 5. ETF Fluorescence














a The SD is derived from the average
activities of five normal human liver
or cultured skin fibroblast samples.
b Literature-reported value.25
c ND p not detectable.
Figure 8. Mild perivascular chronic inflammatory cell cuffing in
postmortem patient brain. Scattered perivascular lymphocytes (ar-
rows) cuff the blood vessels in the brain stem of patient 1. a,
Hematoxylin and eosin stain (640# magnification) and the ne-
ocortical white matter. b, LCA immunohistochemistry stain (640#
magnification). This inflammatory cell infiltrate is also accompa-
nied by some hemosiderin-laden macrophages, seen only in the
deep white matter of the centrum semiovale and the brain stem
but not in gray matter or leptomeninges where the acute damage
was most severe. Neither of these findings appears to be related
to the child’s acute demise; rather, they appear to be chronic.
These changes are reminiscent of, though not as severe as, those
reported in X-linked adrenoleukodystrophy (MIM 300100).
deficiency) and, when present, are usually considered sec-
ondary to recurrent episodes of hypoglycemia. However,
150% of patients with a deficiency of LCHAD/MTP man-
ifest neurological symptoms with demonstrable neuro-
pathology, including demyelination in peripheral neu-
rons.35–37 Although LCHAD/MTP has been found to be
highly expressed in various neurons, its function remains
unclear, which is largely due to the common perception
that long-chain ACADs are not present in the CNS to pro-
vide substrate to the MTP.12 The finding that ACAD9 is,
in fact, expressed in the CNS in humans and the chronic
neuronal abnormalities seen in the ACAD9-deficient pa-
tients strongly support a previously unappreciated but im-
portant role for mitochondrial long-chain fatty acid b-
oxidation in human neuronal tissue. Since brain does not
rely on mitochondrial b-oxidation of long-chain fatty ac-
ids for energy, this pathway must have alternative func-
tions in the CNS. One possible role for ACAD9 is in the
recycling of complex neural lipids and production of in-
termediate metabolites for synthetic pathways. It is un-
usual that both patients 2 and 3 chronically secreted large
amounts of acetylcarnitine in their urine. However, this
supports the presence of a defect in lipid remodeling in
these patients, with wasting of acetylcarnitine induced by
reduced channeling of medium-chain substrates to lipid
synthesis from a pathway involving ACAD9.
Alternative splicing of pre-mRNAs is widely used by
higher eukaryotes to generate different protein isoforms
in specific cell or tissue types and is especially prominent
in humans in brain, liver, and testis.38 Between one-third
and two-thirds of all human genes are estimated to un-
dergo alternative splicing, and the disruption of this pro-
cess has been implicated in several human diseases.39,40
Our studies have identified two ACAD9 protein isoforms
corresponding in size to the predicted products of two
ACAD9 messages generated by alternative splicing. Da-
tabase analysis and subcellular fractionation indicate that
each isoform localizes to a different subcellular location
on the basis of the targeting signals present in each (figs.
5a–5e, 6a, and 6b). Interestingly, patients 1 and 2 show
abnormalities in the cellular distribution of ACAD9 pro-
tein (fig. 5a and 5b), consistent with the possibility that
disruption of alternative splicing is occurring.
The 4-bp insertion in the promoter region of one allele
of patient 1 clearly impairs transcription of this allele in
vivo and in vitro and constitutes a pathologic mutation.
However, the complexity of the ACAD9 gene and its
transcripts hindered our ability to elucidate the molecular
defect in the three remaining mutant ACAD9 alleles avail-
able for examination. Regardless, cDNA amplification ex-
periments unequivocally demonstrated that both patients
1 and 2 lacked normal full-length ACAD9 message in liver
and/or fibroblasts. The presence of multiple abnormal spe-
cies in patient mRNA, with apparent deletions of coding
exons, obviously implicates a defect in RNA splicing. The
identification of only one (and sometimes no) mutations
in clear-cut genetic disorders is a relatively common phe-
nomenon and has been reported in as many as 5%–10%
of cases of enzymatically proven MCAD and VLCAD de-
ficiency,41–43 whereas, in the case of metabolic enzymes
that are primarily active in brain—such as GTP cyclohy-
drolase—no mutations have been reported in 140% of the
patients with deficient enzymatic activity.11 In these pa-
tients, as in ours, the assumption is that other intronic or
untranscribed sequence changes are responsible for the
deficiency.39
The ACAD9 gene has a unique 5′ UTR compared with
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Allele 1    or  b  or    or   or 
Allele 2    or    or    or   or 
Patient 2:
Allele 1   or       
Allele 2   or       
a Novel mutation, not in dbSNP.
b The 787TrC variation was not seen in the cDNA sequence, indicating it is on the same allele with the INS4TAAG
mutation.
the other ACAD genes. The RXR heterodimer pathway
PPARa/RXR regulates expression of most of the enzymes
of b-oxidation involved in energy homeostasis (includ-
ing VLCAD) and is a major drug target for treating com-
mon diseases, such as metabolic syndrome.44 Rapid use of
carbons from fatty acids for synthesis of certain complex
lipids through b-oxidation is known to be critical for the
host defense system during acute phase response to in-
fection or cytokine stimulation and includes up-regulation
of enzymes involved in synthesis and degradation of lipids
such as glycosphingolipids and ceramides.45 The RXR-as-
sociated pathway is largely inactive under these condi-
tions, and the b-oxidation enzymes that are regulated by
PPARa/RXR are down-regulated, including VLCAD.46
However, the NRF-1–associated regulatory pathway is ac-
tivated in response to stimulation of cytokines or stress.21
Control of expression of the ACAD9 gene by NRF-1 sug-
gests that it could be regulated opposite of other ACAD
genes under conditions of cellular stress or stimulation of
cytokines. In fact, cytokine stimulation of ACAD9-defi-
cient and normal fibroblasts supports this (table 4). Par-
ticipation of ACAD9 in a pathway that is rapidly induced
by cytokines suggests a unique role for long-chain fatty
acid b-oxidation in acute phase response upon infection.
In summary, we present the first report, to our knowl-
edge, of genetic defects in ACAD9. The dramatic nature
of the clinical presentations seen in these patients makes
it imperative to learn the frequency of this disorder in
individuals with unexplained liver failure, cerebellar
stroke, and cardiomyopathy of unknown etiology and to
characterize the full spectrum of symptoms in this disease.
Additional study of this enzyme is likely to provide us
with new insights into the pathogenesis of disorders of
fat metabolism in humans.
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